ENTITY
Samsung Biologics

Samsung Biologics (207940 KS)

524
Analysis
Health Care • South Korea
Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.
more
•27 Nov 2025 00:09•Broker

Mirae Asset Minutes [2025: Volume 22]Biweekly strategy meeting recap

We expect AI adoption to drive meaningful price, volume, and cost improvements in 2026, supporting strong momentum in the ad segment.

Logo
285 Views
Share
•12 Nov 2025 20:52•Broker

Mirae Asset Minutes [2025: Volume 21]Biweekly strategy meeting recap

With the BOK expected to keep the base rate unchanged through 2H25, market interest rates have begun to rise. This is favorable for banks’ NIMs.

Logo
210 Views
Share
•31 Oct 2025 19:58•Broker

Mirae Asset Minutes [2025: Volume 20]Biweekly strategy meeting recap

Global equities are likely to remain on an upward trend, supported by favorable liquidity conditions and optimism surrounding AI ecosystem growth

Logo
529 Views
Share
•29 Oct 2025 19:45•Broker

Mirae Asset Minutes [2025: Volume 20] Biweekly Strategy Meeting Recap

Global equities are likely to remain on an upward trend, supported by favorable liquidity conditions and optimism surrounding AI ecosystem growth

Logo
514 Views
Share
•15 Oct 2025 19:52•Broker

Mirae Asset Minutes [2025: Volume 19]Biweekly strategy meeting recap

While AI-related demand from hyperscalers and governments is surging, demand for commodity memory remains uncertain, leading to limited capacity...

Logo
476 Views
Share
x